Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AVNS vs DCTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 3–7 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: AVNS 1 – 5 DCTH Matrix Metrics: AVNS 7 – 3 DCTH

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Avanos Medical, Inc. (AVNS) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AVNS carries a Unified Composite Score of 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin).

  • Composite vs. Pillar Nuance: While AVNS currently prints a higher short-term Unified Composite Score (56.7/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (3–7 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 5.4% operating margin) and revenue trajectory (+70.7% vs. +8.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVNS vs DCTH
AVNS NYSE
Avanos Medical, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$24.99
+0.04% 1D
Market Cap $1.2B
TTM Revenue $716M
Forward P/E 20.0x
Beta / 30D Vol 1.22β · 6% Vol
Unified Composite Score
56.7 / 100 HOLD
Tech 75.0 Fund 59.0 Flow 50.0 Mom 46.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.0 · SMA20: $24.93 · SMA50: $24.90
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96

6-Pillar Scorecard Institutional Category Breakdown (AVNS 1 – 5 DCTH)

Columns: Metric · AVNS · DCTH
1. Valuation Multiples AVNS
Forward P/E 20.0x N/M
Trailing P/E 30.7x 133.6x
PEG Ratio N/M 1.60x
EV / Revenue 1.6x 6.3x
2. Growth & Scale DCTH
Revenue Growth (YoY) +8.8% +70.7%
Earnings Growth (YoY) -21.7% +750.0%
TTM Revenue (USD) $716M $110M
Market Cap $1.2B $743.8M
3. Profitability & Quality DCTH
Gross Margin 50.0% 87.6%
Operating Margin 5.4% 5.2%
Net Profit Margin -10.4% 6.0%
Return on Equity (ROE) -9.2% 5.4%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $56M EBITDA $20M
Cash Flow Margin 7.8% EBITDA Mgn 18.3%
Net Cash / Leverage $16.76 Book/Sh · -9.2% ROE $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 33.0% (50th %ile) 109.3% (43rd %ile)
Put/Call OI Skew N/A 0.11x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 44.6% of Rev ($319M) 82.4% of Rev ($91M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVNS (7) vs DCTH (3)
Institutional Metric AVNS DCTH Criterion Row Edge
Market Capitalization
Scale
$1.2B $743.8M Larger Scale AVNS
Trailing P/E Ratio
Valuation
30.7x 133.6x Lower Multiple AVNS
Forward P/E Ratio
Valuation
20.0x N/M Lower Multiple AVNS
Revenue Growth (YoY)
Growth
+8.8% +70.7% Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.4% 5.2% Higher Margin AVNS
Net Profit Margin
Profitability
-10.4% 6.0% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
-9.2% 5.4% Higher ROE DCTH
52-Week Range Position
Momentum
97% ($9–$25) 80% ($8–$23) Stronger Trend AVNS
Beta / 30D Volatility
Risk Regime
1.22β · 6% Vol 1.63β · 131% Vol Lower Realized Risk AVNS
Unified Institutional Score
Composite Signal
56.7 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite AVNS
Trailing 12M Revenue (USD)
Operating Scale
$716M $110M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
50.0% 87.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.6x EV/Rev 1.60x PEG · 6.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$56M EBITDA ($16.76 Book/Sh · -9.2% ROE) $20M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVNS +0.32 pp
AVNS: +0.16% · DCTH: -0.16%
3M Horizon DCTH +13.72 pp
AVNS: +1.13% · DCTH: +14.85%
6M Horizon AVNS +79.47 pp
AVNS: +90.76% · DCTH: +11.29%
1Y Horizon AVNS +70.75 pp
AVNS: +112.68% · DCTH: +41.93%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVNS vs DCTH. Trailing 12-month operating profitability (AVNS 5.4% vs DCTH 5.2%) and valuation multiples (AVNS 20.0x vs DCTH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AVNS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$716M
Gross Margin50.0%
Op. Margin5.4%
ROE / Fwd P/E-9.2% · 20.0x
DCTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$110M
Gross Margin87.6%
Op. Margin5.2%
ROE / Fwd P/E5.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVNS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 33.0%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVNS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVNS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.2B market capitalization and 5.4% operating margin.
OpEx & R&D Reinvestment 44.6% of Rev ($319M)
90D Engineering Disclosures 0 Published
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published

Investor FAQ AVNS vs DCTH Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Avanos Medical, Inc. (AVNS) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AVNS carries a Unified Composite Score of 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While AVNS currently prints a higher short-term Unified Composite Score (56.7/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (3–7 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 5.4% operating margin) and revenue trajectory (+70.7% vs. +8.8% YoY).

DCTH leads the Growth & Scale pillar: AVNS posts +8.8% YoY revenue growth and -21.7% YoY earnings growth on $716M TTM revenue (50.0% gross margin, 5.4% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). On trailing 12-month operating scale, AVNS generates $716M in USD-normalized revenue versus $110M for DCTH. In operating R&D and SG&A reinvestment, AVNS deploys 44.6% of Rev ($319M) (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.

AVNS screens cheaper on headline valuation multiples. AVNS trades at 20.0x Forward P/E, 30.7x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (7.8% EBITDA margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVNS (-9.2% ROE) versus DCTH (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AVNS carries 33.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 6% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.